Screening history of cervical cancers in Emilia-Romagna, Italy: Defining priorities to improve cervical cancer screening

European Journal of Cancer Prevention

Volumn 24, Issue 2, 2015, Pages 128-134

  Rossi, Paolo Giorgi ^a   Caroli, Stefania ^a   Mancini, Silvia ^b   De Bianchi, Priscilla Sassoli ^c   Finarelli, Alba C ^c   Naldoni, Carlo ^c   Bucchi, Lauro ^b   Falcini, Fabio ^b  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^c Public Health Authority   (Italy)

Author keywords

Cervical cancer; Human papillomavirus DNA test; Incidence trend; Mass screening; Pap test

Indexed keywords

ADENOCARCINOMA; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CANCER REGISTRY; CANCER SCREENING; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; INVASIVE CARCINOMA; ITALY; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PRIORITY JOURNAL; QUALITY CONTROL PROCEDURES; SQUAMOUS CELL CARCINOMA; TUMOR INVASION; UTERINE CERVIX CANCER; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; DIAGNOSTIC ERROR; EARLY DIAGNOSIS; HEALTH CARE PLANNING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; REGISTER; STANDARDS; STATISTICS AND NUMERICAL DATA; TOTAL QUALITY MANAGEMENT; UTERINE CERVICAL NEOPLASMS; UTILIZATION; VAGINA SMEAR; VIROLOGY;

VIRUS DNA;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; DIAGNOSTIC ERRORS; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HEALTH PRIORITIES; HUMANS; ITALY; MIDDLE AGED; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTIONS; QUALITY IMPROVEMENT; REGISTRIES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84927694805     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0000000000000035     Document Type: Article

References (36)

1. Accetta G, Biggeri A, Carreras G, Lippi G, Carozzi FM, Confortini M, et al. (2010). Is human papillomavirus screening preferable to current policies in vaccinated and unvaccinated women? A cost-effectiveness analysis. J Med Screen 17:181-189.
2. Andrae B, Kemetli L, Sparén P, Silfverdal L, Strander B, Ryd W, et al. (2008). Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst 100:622-629.
3. Anttila A (2007). Cervical cancer screening is effective - the Finnish experience. 64: Copenhagen: Entre Nous, WHO Regional Office. pp. 26-28.
4. Arbyn M, Sanjosé SD, Saraiya M, Sideri M, Palefsky J, Lacey C, et al. (2012). EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer 131:1969-1982.
5. Blackwell DL, Martinez ME, Gentleman JF (2008). Women's Compliance with Public Health Guidelines for Mammograms and Pap tests in Canada and the United States: an analysis of data from the Joint Canada/United States Survey of Health. Womens Health Issues 18:85-99.
6. Bos AB, Rebolj M, Habbema JD, van Ballegooijen M (2006). Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands. Int J Cancer 119:2372-2375.
7. Camilloni L, Ferroni E, Cendales BJ, Pezzarossi A, Furnari G, Borgia P, et al. (2013). Methods to increase participation in organised screening programs: a systematic review. BMC Public Health 13:464.
8. Castle PE, Rodríguez AC, Burk RD, Herrero R, Wacholder S, Hildesheim A, et al. (2011). Long-term persistence of prevalently detected human papillomavirus infections in the absence of detectable cervical precancer and cancer. J Infect Dis 203:814-822.
9. Clegg LX, Hankey BF, Tiwari R, Feuer EJ, Edwards BK (2009). Estimating average annual percent change in trend analysis. Stat Med 28:3670-3678.
10. De Kok IM, van Rosmalen J, Dillner J, Arbyn M, Sasieni P, Iftner T, et al. (2012). Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ 344:e670.
11. Di Felice E, Caroli S, Paterlini L, Campari C, Prandi S, Giorgi Rossi P (2014). Cervical cancer epidemiology in foreign women in Northern Italy: role of HPV prevalence in country of origin. Eur J Cancer Prev (in press).
12. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010). Globocan 2008 cancer incidence and mortality worldwide. IARC Cancer Base N110. Lyon, France: International Agency for Research on Cancer.
13. Giorgi Rossi P, Chini F, Borgia P, Guasticchi G, Carozzi FM, Confortini M, et al. (2012). Human papilloma virus (HPV), cervical cancer incidence and screening uptake: differences among Northern, Central and Southern Italy. Epidemiol Prev 36:108-119.
14. Health Council of the Netherlands (2011). Population screening for cervical cancer. The Hague: Health Council of the Netherlands.
15. IARC Working Group on the Evaluation of Cancer Preventive Strategies Cervix Cancer Screening (2005). IARC Handbooks of Cancer Prevention No. 10. Lyon: IARC.
16. Ingemann-Hansen O, Lidang M, Niemann I, Dinesen J, Baandrup U, Svanholm H, et al. (2008). Screening history of women with cervical cancer: a 6-year study in Aarhus, Denmark. Br J Cancer 98:1292-1294.
17. ISTAT (2007). Struttura e dinamica sociale unit form the Health interview survey: health status and use of health services - years 2004-2005. Roma: ISTAT.
18. Leyden WA, Manos MM, Geiger AM, Weinmann S, Mouchawar J, Bischoff K, et al. (2005). Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst 97:675-683.
19. Lönnberg S, Anttila A, Kotaniemi-Talonen L, Kujari H, Melkko J, Granroth G, et al. (2010). Low proportion of false-negative smears in the Finnish program for cervical cancer screening. Cancer Epidemiol Biomarkers Prev 19:381-387.
20. Lönnberg S, Anttila A, Luostarinen T, Nieminen P (2012). Age-specific effectiveness of the Finnish cervical cancer screening programme. Cancer Epidemiol Biomarkers Prev 21:1354-1361.
21. Morrell S, Taylor R, Wain G (2005). A study of Pap test history and histologically determined cervical cancer in NSW women, 1997-2003. J Med Screen 12:190-196.
22. Nieminen P, Kallio M, Anttila A, Hakama M (1999). Organised vs. spontaneous Pap-smear screening for cervical cancer: a case-control study. Int J Cancer 83:55-58.
23. Peto J, Gilham C, Fletcher O, Matthews FE (2004). The cervical cancer epidemic that screening has prevented in the UK. Lancet 364:249-256.
24. Progressi delle Aziende Sanitarie per la Salute in Italia PASSI (2009). Rapporto Annuale 2009. Available at: http://www.epicentro.iss.it/passi/dati/ScreeningCervicale.asp. [Accessed 26 March 2014].
25. Quinn M, Babb P, Jones J, Allen E (1999). Effect of screening on incidence and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 318:904-908.
26. Ronco G, Pilutti S, Patriarca S, Montanari G, Ghiringhello B, Volante R, et al. (2005). Impact of the introduction of organised screening for cervical cancer in Turin, Italy: cancer incidence by screening history 1992-98. Br J Cancer 93:376-378.
27. Ronco G, Accetta G, Angeloni C, Arbyn M, Barzon L, Biggeri A, et al. (2012). Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors. Epidemiol Prev 36 (3/4 Suppl 1) e1-e72.
28. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, et al. (2013). Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383:524-532.
29. Sasieni P, Castanon A, Cuzick J (2009). Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ 339:b2968.
30. Sasieni PD, Cuzick J, Lynch-Farmery E (1996). Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. Br J Cancer 73:1001-1005.
31. Snijders P J F, Verhoef V M J, Arbyn M, Ogilvie G, Minozzi S, Banzi R, et al. (2013). High-risk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer 132:2223-2236.
32. Sung HY, Kearney KA, Miller M, Kinney W, Sawaya GF, Hiatt RA (2000). Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan. Cancer 88:2283-2289.
33. Viikki M, Pukkala E, Hakama M (1999). Risk of cervical cancer after a negative Pap smear. J Med Screen 6:103-107.
34. World Health Organization (2006). Comprehensive cervical cancer control: a guide to essential practice. Geneva: WHO.
35. Zappa M, Dardanoni G, Giorgi Rossi P, Grazzini G, Naldoni C, Paci E, et al. (2011). The diffusion of screening programmes in Italy, year 2009. Epidemiol Prev 35(5-6 Suppl 5):3-7.
36. Zucchetto A, Ronco G, Giorgi Rossi P, Zappa M, Ferretti S, Franzo A, et al. (2013). Screening patterns within organized programs and survival of Italian women with invasive cervical cancer. Prev Med 57:220-226.